Disney CEO Succession, Chipotle Slump & Market Update – Feb 3, 2026

Disney Names D’Amaro as Next CEO, Market Reacts to Earnings and Government Reopening

Today, February 5, 2026, markets are digesting a series of developments, including a changing of the guard at Disney, earnings reports from Chipotle and Novo Nordisk, and the reopening of the federal government following a brief shutdown. Stock futures are ticking higher this morning, following a negative session yesterday.

Disney Announces CEO Succession

Disney officially announced that Josh D’Amaro, currently Chairperson of Walt Disney Parks and Resorts, will succeed Bob Iger as CEO, beginning on March 18, 2026. D’Amaro’s appointment comes after nearly three decades with the company, making him Disney’s eighth chief executive in its history.

The company’s experiences division, which D’Amaro leads, recently reached $10 billion in quarterly revenue for the first time. Dana Walden, Disney Entertainment Co-Chair, will become Disney’s president and creative chief, reporting directly to D’Amaro. Wall Street was largely unsurprised by the decision, according to reports. Despite the leadership change, Disney’s stock ticked lower yesterday, adding to losses seen earlier in the week following the company’s earnings report. Shares have tumbled more than 40% over the last half decade, while the S&P 500 has climbed more than 80%.

Market Movers: Chipotle, Novo Nordisk, and Eli Lilly

Chipotle shares fell more than 5% after the burrito chain reported sliding traffic for a fourth straight quarter. Same-store sales declined 1.7% in 2025, marking the company’s first annual drop since 2016. Chipotle anticipates flat same-store sales in 2026. Shares are down nearly 33% over the last 12 months. The company has been attempting to entice customers with protein cups and a slower pace of price increases.

Novo Nordisk experienced a significant downturn, with sales and profit growth expected to drop this year. U.S.-listed shares tumbled more than 14% on Tuesday, their worst day in around six months, due to a deal with the Trump administration to cut prices and loss of exclusivity for Wegovy and Ozempic in some countries. CEO Mike Doustdar warned that the company’s situation would worsen before improving.

Conversely, Eli Lilly shares jumped more than 8% in premarket trading today after exceeding analyst expectations on both lines in the fourth quarter. The pharmaceutical giant’s full-year revenue outlook also came in stronger than anticipated, driven by demand for Zepbound and Mounjaro.

Federal Government Reopens

President Donald Trump yesterday signed into law a bill to reopen the federal government, which had been partially closed since Saturday. The deal provides funding for several departments through the end of the fiscal year, but only offers two weeks of stopgap funding for the Department of Homeland Security, requiring further negotiations.

In Washington D.C., Federal Reserve Governor Stephen Miran is leaving his position as chair of the Council of Economic Advisers. Miran had been on leave from the CEA since September, when he was appointed by Trump to fill the unexpired Fed Governor term of Adriana Kugler.

Nvidia Dismisses OpenAI Rumors

In an interview with CNBC’s Jim Cramer, Nvidia CEO Jensen Huang dismissed reports of brewing tensions between his company and OpenAI, stating, “There’s no drama involved.” Nvidia announced plans in September to invest up to $100 billion in OpenAI.